Sinorda Pharmaceutical and Sanyou Biotech sign a strategic cooperation agreement to deeply advance innovative drug research and development.

On August 18, 2023, in Shanghai, China, Guizhou Sinorda Pharmaceutical Co., Ltd. (hereinafter referred to as "Sinorda Pharma") signed a strategic cooperation agreement with Sanyou Biopharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") on an innovative bispecific antibody drug project.

According to the cooperation agreement, Sinorda Pharma will leverage its extensive experience in drug development and clinical cancer immunotherapy, joining forces with Sanyou Bio’s globally leading integrated R&D platform for innovative biopharmaceuticals—as well as its cutting-edge preclinical development technologies—and the company’s world-class, trillion-dollar-plus pipeline of pioneering drug candidates. Together, the two organizations will collaborate synergistically to accelerate the research and development of their product pipeline.

Dr. Hu Pingsheng, CEO of Sinorda Pharma "Sinorda is focused on the research and development of innovative drugs and the industrialization of tumor immunotherapy. Our collaboration with Sanyou Biotech will combine the strengths of both parties, accelerating the drug development process and enabling us to translate groundbreaking innovations into tangible solutions more swiftly—ultimately providing patients with more and better treatment options. It is precisely based on this shared vision that we’ve decided to join forces, working together to advance the development of cutting-edge pharmaceutical products and contributing our part to the global cause of human health."

Dr. Lang Guojun, CEO of SanYou Bio "We are deeply honored to establish this strategic partnership with Sinorda. Sinorda boasts profound expertise in science and medicine, extensive clinical capabilities, and robust experience in industry collaboration. At SanYou Biotech and Sinorda, we share the same core values—dedicating biopharmaceutical technologies to advancing human health. Our complementary strengths will create unparalleled growth opportunities for both companies, while also pioneering a new model of deep strategic cooperation between innovative drug R&D service firms and cutting-edge pharmaceutical enterprises. Together, we are poised to bring groundbreaking advancements that will ultimately benefit patients worldwide."

Signing parties: Dr. Lang Guojun, CEO of Sanyou Bio (left), and Dr. Hu Pingsheng, CEO of Sinorda Pharma (right)

SanYou Bio and the Sinorda Pharmaceutical Team in a Group Photo